Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Melanoma 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Merkel Cell 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Thymoma 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Microsatellite Instability 1Mesothelioma 1

Interventions

Docetaxel 8pembrolizumab 7Pemetrexed 5Carboplatin 5Erlotinib Hydrochloride 4toripalimab 3rociletinib 3fludarabine 3Radiosurgery 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Gemcitabine 3Etoposide 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3lorlatinib 2atezolizumab 2Vinorelbine 2Topotecan 2Radiotherapy 2Platinum 2Itraconazole 2Irinotecan 2Interleukin-2 2Cetuximab 2Albumin-Bound Paclitaxel 2vinflunine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × avelumab × Thoracic × Clear all
NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Pfizer

Phase 1/2 Terminated
223 enrolled 50 charts
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡